Peyronie’s Disease: Pathophysiology and Medical Therapy

  • Jacob Rajfer
  • Nestor Gonzalez-Cadavid
  • Mark Jalkut


Peyronie’s disease is an acquired benign condition with potential significant impact on quality of life that can include pain, penile deformity, and erectile dysfunction (ED). Modern studies have shown the disease to be prevalent. Once thought to resolve spontaneously, it is now known that the disease consists of an active phase and a mature phase, with resolution of pain and rarely resolution of penile deformity. The disease is now known to be caused by a “trapped” inflammatory response resulting from minor trauma, hematoma formation with fibrin deposition, and resultant cytokine activity. The cytokine transforming growth factor-β1 (TGF-(β1) has demonstrated particular importance and is used in creating animal models to study the disease. This abnormal immune response may have a genetic predisposition. Modern molecular techniques, genomics, and proteomics are being applied to better understand the pathways that lead to Peyronie’s disease.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lindsay MB, Schain DM, Grambsch P, et al.: The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991, 146: 1007–1009.PubMedGoogle Scholar
  2. 2.
    Schwarzer U, Sommer F, Klotz T, et al.: The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001, 88: 727–730.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith BH: Subclinical Peyronie’s disease. Am J Clin Pathol 1969, 52: 385–390.PubMedGoogle Scholar
  4. 4.
    Williams JL, Thomas GG: The natural history of Peyronie’s disease. J Urol 1970, 103: 75–76.PubMedGoogle Scholar
  5. 5.
    Gelbard MK, Dorey F, James K: The natural history of Peyronie’s disease. J Urol 1990, 144: 1376–1379.PubMedGoogle Scholar
  6. 6.
    Ralph DJ, Pryor J: Peyronie’s disease. In Textbook of Erectile Dysfunction. Edited by Carson C, Kirby R, Goldstein I. Oxford, UK: Isis; 1999: 515–528.Google Scholar
  7. 7.
    Weidner W, Schroeder-Printzen I, Weiske WH, Vosshenrich R: Sexual dysfunction in Peyronie’s disease: an analysis of 222 patients without previous local plaque therapy. J Urol 1997, 157: 325–328.PubMedCrossRefGoogle Scholar
  8. 8.
    Pryor JP: Peyronie’s disease and impotence. Acta Urol Belg 1988, 56: 317–321.PubMedGoogle Scholar
  9. 9.
    Lopez JA, Jarow JP: Penile vascular evaluation of men with Peyronie’s disease. J Urol 1993, 149: 53–55.PubMedGoogle Scholar
  10. 10.
    Furey CA: Peyronie’s disease: a treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957, 55: 251–266.Google Scholar
  11. 11.
    Jarow JP, Lowe FC: Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997, 158: 1388–1390.PubMedCrossRefGoogle Scholar
  12. 12.
    Devine CJ, Jr., Somers KD, Jordan SG, Schlossberg SM: Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997, 157: 285–290.PubMedCrossRefGoogle Scholar
  13. 13.
    Brock G, Hsu GL, Nunes L, et al.: The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997, 157: 276–281.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen IK, Diegelmann RF, Crossland MC: Wound care and wound healing. In Principles of Surgery, edn 6. Edited by Schwartz SI, et al. New York: McGraw-Hill, Inc.; 1994: 279–303.Google Scholar
  15. 15.
    El-Sakka AI, Selph CA, Yen TS, Dahiya R, Lue TF: The effect of surgical trauma on rat tunica albuginea. J Urol 1998, 159: 1700–1707.PubMedCrossRefGoogle Scholar
  16. 16.
    Somers KD, Dawson DM: Fibrin deposition in Peyronie’s disease plaque. J Urol 1997, 157: 311–315.PubMedCrossRefGoogle Scholar
  17. 17.
    El-Sakka AI, Hassoba HM, Pillarisetty RJ, et al.: Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158: 1391–134.PubMedCrossRefGoogle Scholar
  18. 18.
    El-Sakka AI, Hassoba HM, Chui RM, et al.: An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158: 2284–2290.PubMedCrossRefGoogle Scholar
  19. 19.
    Casini A, Ceni E, Salzano R, et al.: Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 1997, 25: 361–367.PubMedCrossRefGoogle Scholar
  20. 20.
    Poli G: Oxidative damage and fibrogenesis. Free Radic Biol Med 1997, 22: 287–305.PubMedCrossRefGoogle Scholar
  21. 21.
    Poli G: Pathogenesis of liver fibrosis: role of oxidative stress. Molecular Aspects of Medicine 2000, 21: 49–98.PubMedCrossRefGoogle Scholar
  22. 22.
    Geller DA, Billiar TR: Molecular biology of nitric oxide synthases. Cancer Metast Rev 1998, 17: 7–23.CrossRefGoogle Scholar
  23. 23.
    Nathan C: Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997, 100: 2417–2423.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Gonzalez-Cadavid NF, Magee TR, Ferrini M, et al.: Gene expression in Peyronie’s disease. Int J Impot Res 2002, 14: 361–374.PubMedCrossRefGoogle Scholar
  25. 25.
    Chilton CP, Castle WM, Westwood CA, Pryor JP: Factors associated in the aetiology of Peyronie’s disease. Br J Urol 1982, 54: 748–750.PubMedCrossRefGoogle Scholar
  26. 26.
    Nyberg LM, Jr., Bias WB, Hochberg MC, Walsh PC: Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982, 128: 48–51.PubMedGoogle Scholar
  27. 27.
    Ralph DJ, Schwartz G, Moore W, et al.: The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997, 157: 291–294.PubMedCrossRefGoogle Scholar
  28. 28.
    Stewart S, Malto M, Sandberg L, Colburn KK: Increased serum levels of antielastin antibodies in patients with Peyronie’s disease. J Urol 1994, 152: 105–106.PubMedGoogle Scholar
  29. 29.
    Bystrom J, Rubio C: Induratio penis plastica Peyronie’s disease: clinical features and etiology. Scand J Urol Nephrol 1976, 10: 12–20.PubMedCrossRefGoogle Scholar
  30. 30.
    Ling RS: The genetic factor in Dupuytren’s disease. J Bone Joint Surg Am 1963, 45: 709–718.Google Scholar
  31. 31.
    Scardino P, Scott WW: The use of tocopherols in the treatment of Peyronie’s disease. Ann N Y Acad Sci 1949, 52: 390.Google Scholar
  32. 32.
    Devine CJ, Jr., Horton CE: Surgical treatment of Peyronie’s disease with a dermal graft. J Urol 1974, 111: 44–49.PubMedGoogle Scholar
  33. 33.
    Mynderse LA, Monga M: Oral therapy for Peyronie’s disease. Int J Impot Res 2002, 14: 340–344.PubMedCrossRefGoogle Scholar
  34. 34.
    Chesney J: Peyronie’s disease. Br J Urol 1975, 47: 209–219.PubMedCrossRefGoogle Scholar
  35. 35.
    Carson CC: Potassium para-aminobenzoate for the treatment of Peyronie’s disease: is it effective? Tech Urol 1997, 3: 135–139.PubMedGoogle Scholar
  36. 36.
    Hasche-Klunder R: Treatment of Peyronie’s disease with para-aminobenzoacidic potassium (POTOBA). Urologe A 1978, 17: 224–227.PubMedGoogle Scholar
  37. 37.
    Zarafonetis CJ, Horrax TM: Treatment of Peyronie’s disease with potassium para-aminobenzoate (potaba). J Urol 1959, 81: 770–772.PubMedGoogle Scholar
  38. 38.
    Akkus E, Carrier S, Rehman J, et al.: Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994, 44: 291–295.PubMedCrossRefGoogle Scholar
  39. 39.
    El-Sakka AI, Bakircioglu ME, Bhatnagar RS, et al.: The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol 1999, 161: 1980–1983.PubMedCrossRefGoogle Scholar
  40. 40.
    Colletta AA, Wakefield LM, Howell FV, et al.:. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990, 62: 405–409.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP: The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992, 70: 648–651.PubMedCrossRefGoogle Scholar
  42. 42.
    Teloken C, Rhoden EL, Grazziotin TM, et al.: Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999, 162: 2003–2005.PubMedCrossRefGoogle Scholar
  43. 43.
    Gelbard MK, Walsh R, Kaufman JJ: Collagenase for Peyronie’s disease experimental studies. Urol Res 1982, 10: 135–140.PubMedCrossRefGoogle Scholar
  44. 44.
    Gelbard MK, James K, Riach P, Dorey F: Collagenase versus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 1993, 149: 56–58.PubMedGoogle Scholar
  45. 45.
    Levine LA, Estrada CR: Intralesional verapamil for the treatment of Peyronie’s disease: a review. Int J Impot Res 2002, 14: 324–328.PubMedCrossRefGoogle Scholar
  46. 46.
    Lee RC, Ping JA: Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990, 49: 463–466.PubMedCrossRefGoogle Scholar
  47. 47.
    Levine LA, Goldman KE, Greenfield JM: Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002, 168: 621–625.PubMedCrossRefGoogle Scholar
  48. 48.
    Kelami A: Classification of congenital and acquired penile deviation. Urol Int 1983, 38: 229–233.PubMedCrossRefGoogle Scholar
  49. 49.
    Duncan MR, Berman B, Nseyo UO: Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991, 25: 89–94.PubMedCrossRefGoogle Scholar
  50. 50.
    Ahuja S, Bivalacqua TJ, Case J, et al.: A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl 1999, 20: 444–448.PubMedGoogle Scholar
  51. 51.
    Benson RC Jr, Knoll LD, Furlow WL: Interferon alpha 2 b in the treatment of Peyronie’s disease [abstract]. J Urol 1991, 145 (suppl): 1342.Google Scholar
  52. 52.
    Colombo F, Baroni P, Serrago M, et al.: Shock waves in Le Peyronie’s disease: two years experience. Eur Urol 1997, 35 (suppl 2): 124.Google Scholar
  53. 53.
    Manikandan R, Islam W, Srinivasan V, Evans CM: Evaluation of extracorporeal shock wave therapy in Peyronie’s disease. Urology 2002, 60: 795–799.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Jacob Rajfer
  • Nestor Gonzalez-Cadavid
  • Mark Jalkut

There are no affiliations available

Personalised recommendations